Much EV development prompts digital innovation, yet tried-and-true analog approaches, such as LLCs offer measurable benefits.
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback